cgp 42112a has been researched along with Diabetes Mellitus, Type 2 in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kamata, K; Kobayashi, T; Matsumoto, T; Taguchi, K | 1 |
1 other study(ies) available for cgp 42112a and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Angiotensin II type 2 receptor-dependent increase in nitric oxide synthase activity in the endothelium of db/db mice is mediated via a MEK pathway.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Aorta; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Disease Models, Animal; Dose-Response Relationship, Drug; Endothelium, Vascular; Enzyme Activation; Flavonoids; Losartan; Male; MAP Kinase Kinase 1; MAP Kinase Kinase 2; MAP Kinase Kinase Kinases; Mice; Mice, Inbred C57BL; Nitric Oxide; Nitric Oxide Synthase Type III; Oligopeptides; Phosphorylation; Protein Kinase Inhibitors; Receptor, Angiotensin, Type 2; Signal Transduction; Time Factors; Vasodilation; Vasodilator Agents | 2012 |